CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Opportunity knocks thrice for the iconic growth investor.

CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.

If you are trying to work out whether CRISPR Therapeutics is attractively priced or not, starting with the recent share ...

However, there are certain things AI can't do -- and may never be able to do. One of them is to cure diseases. Biotech companies that develop and market breakthrough therapies for, thus far, ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first ...

CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. First, let's talk a bit about ...